by Stacey Hawkins | Aug 20, 2019 | Clinical Trials
Phase I and II Clinical Trials Every drug in clinical use today, from the latest CAR-T treatment to older cholesterol-lowering statins, share one thing in common: they have all successfully navigated the rigorous clinical trials process. This is no small feat, as only... 
by Stacey Hawkins | Jan 22, 2019 | Immunotherapies
Further Down The Cancer Treatment Road With CARs Chimeric antigen receptor (CAR) T-cell therapies have captured the imagination of both scientists and the public. The ability to genetically alter a patient’s own cells to fight cancer has revolutionized the treatment... by Stacey Hawkins | Sep 27, 2018 | Immunology
Attack Of The Tregs!! No matter what it sounds like, this subset of helper T-cells aren’t invaders from another planet. Nope, Tregs, or regulatory T-cells, come from New Jersey (don’t say it!) and elsewhere. They suppress the immune system. These newcomers to the... 
by Stacey Hawkins | Jun 21, 2018 | Drug Delivery
RED BLOOD CELLS: READY FOR DOUBLE-DUTY? Biotech Primer WEEKLY talks a lot about white blood cells, with good reason. These powerful immune cells defend us against pathogens and have recently been adapted to fight cancer as CAR-T cells. What about the body’s... by Stacey Hawkins | Feb 22, 2018 | Clinical Trials
From The Lab To The Patient In this issue of the Biotech Primer WEEKLY we will recap the past seven issues that highlight the journey a molecule takes from the lab to the patient. Beginning in the 1980’s, scientists took a new tack in developing drugs. They...
